PD-L1≥90%的非小细胞肺癌一线帕博利珠单抗疗效更优
这项多中心回顾性分析纳入187例PD-L1≥50%且EGFR/ALK阴性的非小细胞肺癌患者,评估一线帕博利珠单抗疗效与PD-L1表达水平的关系。结果显示PD-L1 90%-100%组较50%-89%组的ORR、mPFS和mOS均显著更优。
要点
- PD-L1≥90%者一线帕博利珠单抗的ORR达60.0%,显著高于50%-89%者的32.7%。
- PD-L1≥90%者mPFS为14.5个月,50%-89%者为4.1个月,HR 0.50。
- PD-L1≥90%者mOS未达到,50%-89%者为15.9个月,HR 0.39。
核心结论
- 在PD-L1≥50%且EGFR/ALK阴性的NSCLC中,一线帕博利珠单抗的临床结局在PD-L1≥90%者中显著改善。
研究设计与样本
- 多中心回顾性分析,纳入187例接受商业帕博利珠单抗一线治疗、PD-L1≥50%且EGFR/ALK阴性的NSCLC患者。
主要发现
- 整体ORR为44.4%(95%CI 37.1%-51.8%),mPFS为6.5个月(95%CI 4.5-8.5),mOS未达到。
- 缓解者的中位PD-L1表达水平显著高于疾病稳定或进展者(90% vs 75%,P<0.001)。
- PD-L1 90%-100%组(N=80)较50%-89%组(N=107)的ORR显著更高(60.0% vs 32.7%,P<0.001)。
- PD-L1 90%-100%组较50%-89%组的mPFS显著更长(14.5 vs 4.1个月,HR 0.50,95%CI 0.33-0.74,P<0.01)。
- PD-L1 90%-100%组较50%-89%组的mOS显著更长(未达到 vs 15.9个月,HR 0.39,95%CI 0.21-0.70,P=0.002)。
临床怎么用
- 对PD-L1≥50%的NSCLC患者,可结合PD-L1具体表达水平(如≥90%)辅助一线治疗选择。
- PD-L1≥90%者接受一线帕博利珠单抗的获益更显著,支持在临床决策中细化PD-L1分层。
局限性
- 本研究为多中心回顾性分析,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor pembrolizumab improves survival compared with platinum-doublet chemotherapy. Whether higher PD-L1 levels within the expression range of 50%-100% predict for even greater benefit to pembrolizumab is currently unknown. PATIENTS AND METHODS: In this multicenter retrospective analysis, we analyzed the impact of PD-L1 expression levels on the overall response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) in patients who received commercial pembrolizumab as first-line treatment of non-small-cell lung cancer (NSCLC) with a PD-L1 expression of ≥50% and negative for genomic alterations in the EGFR and ALK genes . RESULTS: Among 187 patients included in this analysis, the ORR was 44.4% [95% confidence interval (CI) 37.1% to 51.8%], the mPFS was 6.5 months (95% CI 4.5-8.5), and the mOS was not reached. The median PD-L1 expression level among patients who experienced a response to pembrolizumab was significantly higher than among patients with stable or progressive disease (90% versus 75%, P < 0.001). Compared with patients with PD-L1 expression of 50%-89% (N = 107), patients with an expression level of 90%-100% (N = 80) had a significantly higher ORR (60.0% versus 32.7%, P < 0.001), a significantly longer mPFS [14.5 versus 4.1 months, hazard ratio (HR) 0.50 (95% CI 0.33-0.74), P < 0.01], and a significantly longer mOS [not reached versus 15.9 months, HR 0.39 (95% CI 0.21-0.70), P = 0.002]. CONCLUSION: Among patients with NSCLC and PD-L1 expression of ≥50% treated with first-line pembrolizumab, clinical outcomes are significantly improved in NSCLCs with a PD-L1 expression of ≥90%. These findings have implications for treatment selection as well as for clinical trial interpretation and design.
引用
- Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019. PMID: 31435660. doi:10.1093/annonc/mdz288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。